TST105 / Transcenta - LARVOL DELTA

Characterization of novel humanized FGFR2b antibody-based ADCs site-specifically conjugated with topoisomerase I inhibitor payload in preclinical tumor models (AACR 2025) - "Anti-tumor efficacy was evaluated in FGFR2b-positive tumor cell line-derived xenograft (CDX) models in mice. 38D4 specifically binds to FGFR2b with a higher affinity than the Bemarituzumab-analog. FGFR2b ADC TST105 demonstrated the high potency, strong anti-tumor activity and bystander effect in the preclinical studies, which support further investigations of TST105 in FGFR2b positive solid tumors."

Preclinical • Biliary Cancer • Cholangiocarcinoma • Colorectal Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • FGFR2